InMed Pharmaceuticals (INM) investor relations material

Key scientific insights and drug development progress

• Lead candidate INM-901 targets CB1 and CB2 receptors to address neuroinflammation in Alzheimer's, showing neuroprotective and neurogenesis effects in preclinical models.

• INM-901 demonstrated significant reduction in pro-inflammatory biomarkers and improved cognition and memory in long-term animal studies, with dose-dependent effects.

• INM-089, targeting dry age-related macular degeneration, preserved retinal function and protected retinal pigment epithelium in animal models.

• INM-755 completed phase IIa for chronic itch in epidermolysis bullosa, showing meaningful improvement in most patients above standard cream.

• All candidates leverage CB1/CB2 signaling, with robust preclinical and early clinical data supporting further development.

Strategic milestones and forward-looking statements

• INM-901 and INM-089 are on similar development timelines, with a pre-IND FDA meeting for INM-901 targeted for Q3 and clinical trials planned for 2027.

• Additional IND-enabling pharmacology and toxicology studies are ongoing to support regulatory submissions.

• INM-755 is seeking a partner for phase III advancement due to resource constraints.

• The company is exploring strategic partnerships, co-development, and investment to accelerate programs.

• Upcoming data from ongoing studies will be reported in the next few weeks.

Financial and corporate overview

• Cash position of $7 million as of December 31, sufficient to fund operations into Q4.

• Market cap is approximately $4 million, with about 7 million shares outstanding (fully diluted).

• Leadership and board have deep experience across biotech, pharma, and capital markets.

• Strong intellectual property portfolio covers compound classes, modifications, uses, and manufacturing, supporting both in-house and out-licensing strategies.

• Chemistry manufacturing control (CMC) expertise provides operational advantage for future partnerships.